AbbVie, InterMune Sue EMA on Data Confidentiality

AbbVie Inc. and InterMune Inc. could derail the European Medicines Agency's (EMA) carefully timetabled introduction of a new data transparency regime on Jan. 1, 2014, by seeking court injunctions preventing the disclosure of clinical trial data for their respective principal products, Humira (adalimumab) and Esbriet (perfidenone).